<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543801</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2022</org_study_id>
    <nct_id>NCT02543801</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty</brief_title>
  <official_title>A Prospective, Randomized Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kootenai Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kootenai Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two routinely used drug combinations for periarticular injection
      following total hip arthroplasty for pain control. One group will receive liposomal
      bupivacaine, bupivacaine, clonidine, epinephrine and ketorolac. The other group will receive
      ropivacaine, clonidine, epinephrine and ketorolac.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Hospitalization duration, an expected average of 48 hours</time_frame>
    <description>Self-reported pain score 1-10 (1=no pain - 10=worst possible pain experienced)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic consumption</measure>
    <time_frame>For the hospitalization duration,an expected average of 48 hours</time_frame>
    <description>Total amount of narcotics administered as calculated in oral morphine equivalent dose for duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospitalization duration, an expected average of 48 hours</time_frame>
    <description>Measured in hours from start of surgery to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine Clonidine Epinephrine Ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Periarticular injection</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Included as an element of the Liposomal bupivacaine intervention periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Duraclon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Included as an element of both interventions as a standard of care periarticular injection</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hip Arthritis (osteoarthritis, post traumatic, inflammatory, and avascular necrosis)

        Exclusion Criteria:

          -  Current use of opioid drugs

          -  Revision surgery

          -  Surgical complication (femoral fracture with implant insertion)

          -  Inability to provide Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Bowen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kootenai Health</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 22, 2016</lastchanged_date>
  <firstreceived_date>August 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
